XACT OMXC25 ESG (UCITS ETF)

The fund is an exchange-traded index fund and its objective is to follow the performance of the OMX Copenhagen 25 ESG Responsible Net Index to attain returns that correspond as closely as possible to the performance of this index. OMX Copenhagen 25 ESG Responsible Net Index is a market-value weighted index consisting of the 25 most-traded equities on the Copenhagen Stock Exchange that meet the sustainability requirements of the index. For further information please refer to the fund's prospectus. The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).

Performance

23.08.2024


| YTD | 1 week | 1 mth. | 3 mån | 1 year | 5 years | 10 years |
|--------|--------|--------|-------|--------|---------|----------|
| 10.29% | -0.06% | 1.02% | 0.39% | 15.78% | 89.79% | - |

Average performance

| Average. perf. | 2 years | 3 years | 5 years | 10 years |
|--------------------|---------|---------|---------|----------|
| Fund ¹ | 9.37% | 3.79% | 14.30% | - |
| Index ² | 9.82% | 4.27% | 14.81% | - |

¹ Calculated on the fund's monthly closing price

Five years performance



Portfolio

Stocks 99.69% Bonds and Cash 0.31%

As of: 31.07.2024

Fund manager



Christian Sopov

Experience in the fund industry 2007. Portfolio Manager since 23 January 2019.

Main category Equity Fund Risk 4

Rate 208.54 (23.08.2024)

Reporting Currency DKK

Price/Trade Exchange traded

Total Rating™ ★★★★

Minimum investment 1 unit
Monthly savings Traded on the Internet No
Management Fee 0.2%
Entry charge 0%
Exit charge 0%

Fund assets 7,928 MSEK

Distribution per fund unit -

Distribution date -Fund, date of launch 29.01.2019 Share class, date of 29.01.2019

launch

Largest holdings

| Novo Nordisk A/S Class B | 13.44% |
|--------------------------|--------|
| DSV AS | 11.52% |
| Vestas Wind Systems A/S | 9.69% |
| Novonesis AS Class B | 8.58% |
| Danske Bank A/S | 7.74% |
| Coloplast A/S Class B | 7.59% |
| Genmab A/S | 6.99% |
| Pandora A/S | 5.00% |
| Orsted A/S | 4.76% |
| Zealand Pharma A/S | 2.91% |
| | |

² Benchmark index: OMX Copenhagen 25 ESG Responsible Net Index. The information in the table refers to the benchmark index valid at any given time. In the event the fund has previously had other benchmark indexes, this information can be found in the fund's annual report.

The fund's fact sheet, risk level, fund rules and prospectus are available at www.handelsbanken.se/funds. Handelsbanken does not assume liability for any errors in the information.

www.handelsbanken.se/funds

Handelsbanken